SUMMARY Plasma total biopterin concentration was measured by bioassay in 59 infants with hyperphenylalaninaemia and in 50 children with developmental regression and or movement disorder with normal plasma phenylalanine concentrations. In infants with raised phenylalanine concentrations plasma biopterin concentrations were significantly raised in proportion to the phenylalanine values. Five patients had plasma biopterin concentrations at the extremes of the range, and of these two had defective biopterin metabolism. One with low plasma biopterin concentration apparently had a partial defect of biopterin synthesis but died before investigations were complete. One with high plasma biopterin concentration, even when phenylalanine concentrations had fallen to the normal range, had dihydropteridine reductase deficiency. In this patient concentrations of homovanillic acid and 5-hydroxyindolacetic acid in the cerebrospinal fluid (CSF) were severely reduced.
Tetrahydrobiopterin is the essential cofactor for three hydroxylation reactions, the conversion of phenylalanine to tyrosine, tyrosine to L-dopa, and tryptophan to 5-hydroxytryptophan.' These last two reactions are the rate limiting steps of catecholamine and serotonin synthesis. Deficiency of tetrahydrobiopterin, due either to defective biopterin synthesis from guanosine triphosphate or dihydropteridine reductase deficiency ( Fig. 1) , is the cause of hyperphenylalaninaemia in 1-3% of infants detected on routine neonatal screening.25 Children with deficiency of tetrahydrobiopterin may develop progressive neurological disease, in which movement disorder is a prominent feature and which is unresponsive to a low phenylalanine diet and due in large part to deficiency of neurotransmitter amines. We wished to assess whether measurement of plasma total biopterin concentrations would help in distinguishing patients with hyperphenylalaninaemia due to defective biopterin metabolism from those with phenylalanine hydroxylase deficiency.
Symptomless patients with normal plasma phenylalanine concentrations, yet defective biopterin synthesis, have been described,6 and others may have symptoms, and/or phenylalanine accumulation, only when exposed to an excessive phenylalanine intake. 16 Initially, these measurements were not available in our own laboratory, and the assays were done by Dr M Tricklebank, London.
Results
Infants with phenylketonuria. In comparison with healthy children6 and infants with neurological disorder, plasma biopterin concentrations were markedly raised (Fig. 2) . Generally, the least rise was present in the infants with phenylalanine concentrations closest to the normal range, but even in the group with phenylalanine concentrations below 400 [smol/I (6-6 mg/100 ml) the mean plasma biopterin concentration (3-16 ng/ml) was significantly raised in comparison with the mean (2-2 ng/ml) for infants under 2 months of age with neurological disorder (t=2-23, 0-02> p<0.05). In The correlation between plasma biopterin and phenylalanine concentrations was closer for patients on a low phenylalanine diet (r=0-89, t=2-941, 0-001> p<0-0l).
Five patients had plasma biopterin concentrations at or outside 2SDs from the means for other patients with similar phenylalanine concentrations ( Table 1) . Further investigation of biopterin metabolism in three of the five gave normal results as follows. In one patient with an initial biopterin concentration of 18 ng/ml plasma biopterin concentration fell to the normal range (2.1 ng/ml) when a plasma phenylalanine was 60 [imoUl (1 mg/100 ml), and no further investigation was undertaken. In another patient with an initial biopterin concentration of 20*5 ng/ml the value fell to 6-6 ng/ml when phenylalanine was 700 ismoll (11-6 mg/100 ml), and an oral load of tetrahydrobiopterin produced no change in phenylalanine or tyrosine concentrations (Fig. 3 
Time (h) Fig. 3 Plasma phenylalanine ( ) and tyrosine ---) concentrations after a single oral dose of tetrahydrobiopterin (BH4) 7-5 mglkg, in a patient with dihydropteridine reductase deficiency (A) and in a patient with phenylalanine hydroxylase deficiency (a).
Conversion: SI to traditional units-Phenylalanine: 1 mmoVl= mg/100 ml. activity. Investigations in two remaining patients, who proved to have abnormal biopterin metabolism, are described in more detail below.
Case 1: deficiency of dihydropteridine reductase activity. This infant had the highest initial plasma biopterin concentration (21-6 ng/ml) of the series. When retested after phenylalanine concentrations Neurological aspects of biopterin metabolism 133 had fallen to 240 ismol/l plasma biopterin concentration was still high at 16-0 ng/ml. These results suggested a deficiency of dihydropteridine reductase activity, which was confirmed on further investigation. Urine pterin analysis gave a biopterin: neopterin: creatinine ratio of 814 (expected value 9-32, Dr A Niederwieser), and plasma phenylalanine concentration fell from 344 to 99 !smol/l (5.7 to 1-6 mg/100 ml) while tyrosine rose from 39 to 65 iimol/l in response to administration of tetrahydropteridine. There was no detectable dihydropteridine reductase activity in the liver, although phenylalanine hydroxylase activity was normal (Dr F Rey, Paris). Concentrations of total biopterin in CSF were raised (9-11 ng/ml) ( Table 2 ) compared with the results found in the patients with neurological disorders (Table 3 ), but homovanillic (19 ng/ml) and 5-hydroxyindolacetic (3.5 ng/ml) acids were markedly reduced and were not increased by a single dose of tetrahydropteridine (7-5 mg/kg) ( Table 2 ). The patient showed only minor clinical abnormalities (hypotonia and hypomobility).
Administration of L-dopa (10-12 mg/kg), carbidopa (as Sinemet-110), and 5-hydroxytryptophan 10-12 mg/kg from 3 months of age led to a rise in the amine metabolite concentrations in CSF ( Table 2) and disappearance of the clinical signs. The patient made good developmental progress for the next 18 months, although intercurrent illness caused transient hypotonia. At 10 months of age neurotransmitter replacement therapy was temporarily withdrawn during a trial of monotherapy with tetrahydropteridine at a dose of 20 mg/kg/day. After five days the patient became grossly hypotonic and developed an acute oculogyric crisis, which was reversed within hours of reintroduction of L-dopa and 5-hydroxytryptophan. Despite a rise of plasma total biopterin concentration from 11 ng/ml to 73 ng/ml during administration of tetrahydropteridine there was no rise in the already raised CSF total biopterin concentration. Concentrations of homo- Case 2: defective biopterin synthesis. A routine screening test for phenylketonuria was negative on the 10th day when the infant was receiving milk feeds but had developed diarrhoea. Raised phenylalanine concentrations, with an excess of phenylketones in the urine, was first noted at 4 months of age after the start of complete intravenous nutrition for persistent diarrhoea and failure to thrive. At this time the infant weighed only 3-6 kg, had recurrent fits, was severely delayed in development, and was noted to be grossly hypotonic with dyskinetic movements. Plasma biopterin concentration (2-2 ng/ml) was in the normal range despite plasma phenylalanine concentrations above 2000 .tmol/l (33 mg/100 ml) (Fig. 2) . Withdrawal of intravenous treatment led to a fall of phenylalanine to 600 [smol/l within 48 hours, but the infant suddenly collapsed and died. A dried blood spot obtained just before death showed no detectable biopterin activity, and urine analysis by high performance liquid chromatography showed a low total biopterin of 0-475 [tg/ml and high normal neopterin of 5-325 ,tg/ml, with a biopterin:neopterin ratio of 1:11 (the normal for early infancy being 1:2, Professor J Blair). These findings suggested that the infant had a partial defect of biopterin synthesis. Permission for post mortem was refused.
Patients with neurological disorder. The mean (SD) plasma total biopterin concentration for the 50 children was 1-78 (0-86) ng/ml, almost identical to the mean (1-75 ng/ml) found in 10 normal children in a previous study.6 There were no significant differences between groups (Table 3) , and there was no relation between age and plasma biopterin. Parents with dominantly inherited tics had similar plasma biopterin concentrations (mean 2.2 ng/ml) to their children. Two patients, one with mental retardation and one with movement disorder, had initial plasma biopterin results at the lower limit of detection (0-2 ng/ml). They were investigated by means of a phenylalanine load (Fig. 4, cases 1 and  2 ). Fasting plasma biopterin concentrations were 1-6 and 1-3 ng/ml, respectively, and the biopterin response to phenylalanine was normal. The low initial readings may have been due to artefact, perhaps caused by delay in specimen handling.
CSF total biopterin concentrations were generally higher (overall mean (SD) 2-9 (0.8) ng/ml) than plasma values ( M) and F3 mother and father of case 3. Plasma phenylalanine concentrations rose to between 420) and 6()t 8moI/l (6-9 and 9 9 mg/l()O ml).
Converston.
Sl to traditional units-Phenylalanine: ImmoVI 16 5 mg/l(10 ml. There was no reflux, and the picture resembled severe achalasia of the cardia. A fasting plasma phenlalanine:tyrosine ratio was <1 in patient and parents, indicating that there was no major impairment of phenylalanine hydroxylation in the liver.
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and tyrosine concentrations to a phenylalanine load in patient and both parents (Fig. 4) was normal. Assay of dihydropteridine activity in a dried blood spot from the patient was also normal (102 [smol NADH/min/ml). CSF homovanillic (38-5 ng/ml) and 5-hydroindolacetic (8-4 ng/ml) acids seemed to be low, although not as strikingly so as in the patient with deficiency of dihydropteridine activity. Therapeutic trials of The results of the present study, showing that infants with raised plasma phenylalanine concentrations due to deficiency of phenylalanine hydroxylase activity have raised plasma biopterin concentrations in proportion to the hyperphenylalaninaemia are consistent with other studies.6 15 Among 59 consecutive infants with persistently raised plasma phenylalanine concentrations two patients, both with plasma biopterin concentrations 2SD from the mean for patients with phenylalanine hydroxylase deficiency (allowing for variation in phenylalanine), proved to have defective biopterin metabolism.
The most useful investigations for confirmation or exclusion of defective biopterin metabolism depended upon whether the initial plasma biopterin was 'high' or 'low'. In the patients with 'high' values measurement of dihydropteridine reductase activity, with repeat plasma biopterin measurement when phenylalanine had fallen to the normal range, enabled a firm diagnosis of dihydropteridine reductase deficiency to be made. In the presence of 'low' initial biopterins urine pterin analysis indicated a partial block in the conversion of neopterin to biopterin. This patient died before an oral load of tetrahydrobiopterin could be given, and the possibility that biopterin deficiency was due to profound malnutrition, rather than to an inborn error, cannot be excluded. 17 In 50 children with neurological disease and without hyperphenylalaninaemia plasma biopterin concentrations were similar to those of healthy children,6 suggesting that in patients with normal phenylalanine concentrations general disturbance of biopterin metabolism is rarely the cause of progressive intellectual loss or extrapyramidal disturbance. CSF biopterin concentrations in children without movement disorder and children with torsion dystonia were similar to those in children with leukaemia (4-2 ng/ml) studied before treatment (unpublished data). CSF biopterin concentrations were lower in children with movement disorder other than torsion dystonia, a finding which can best be explained as due to anatomical or functional abnormality of the brain areas normally contributing to CSF biopterin rather than as the result of a primary defect of biopterin metabolism.
Six adult patients with Huntington's chorea also had normal plasma biopterin and low CSF total biopterin concentrations (1-9 ng/ml) (unpublished observations). A study of 'hydroxylase cofactor activity' in CSF found concentrations equivalent to 20 iimol/l tetrahydrobiopterin (4.2 ng/ml) in adult controls, and patients with movement disorder (Parkinson's disease and Huntington's chorea) again showed a reduction of 50% or more.8
Profoundly low CSF 'hydroxylase cofactor activity' has been reported in several members of two families with torsion dystonia.9 These patients did not manifest the degree of neurological disturbance that might have been expected2 if tetrahydrobiopterin in the central nervous system had indeed been severely reduced. These results contrast with the normal crithidia results in the patients with torsion dystonia described here, although one in whom amine metabolite concentrations were measured did show reduced concentrations of dopamine and serotonin metabolites in the CSF, suggesting that interference with tyrosine and tryptophan hydroxylation might have been present. We speculate that an inhibitor of the aromatic hydroxylases is present in the CSF and brains of some patients with torsion dystonia, which, without direct interference in biopterin synthesis, reduces 'hydroxylase cofactor activity' and amine turnover. The association reported here of achalasia of the cardia with torsion dystonia and a disturbance of amine metabolism is of interest as the pathogenesis of both disorders remains a mystery. 
